Showing results (221-230 of 584) with videos related to
Sort By:
Pageof 59
Plos One|August 23, 2017
Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancerCécile Jovelet, Jordan Madic, Jordi Remon, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 25, 2020
Can radiation-recall predict long lasting response to immune checkpoint inhibitors?Eric Deutsch, Benjamin Besse, Jérôme Le Pavec, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancerJean-Charles Soria, Egbert Smit, David Khayat, et al.Frontiers in Immunology|February 1, 2024
HLA-DR expression in melanoma: from misleading therapeutic target to potential immunotherapy biomarkerKarim Amrane, Coline Le Meur, Benjamin Besse, et al.Journal of Thoracic Disease|June 29, 2018
Do immune checkpoint inhibitors need new studies methodology?Roberto Ferrara, Sara Pilotto, Mario Caccese, et al.Journal of Personalized Medicine|June 2, 2021
Lincp21-RNA as Predictive Response Marker for Preoperative Chemoradiotherapy in Rectal CancerJose Carlos Benitez, Marc Campayo, Tania Díaz, et al.Expert Review of Anticancer Therapy|February 5, 2026
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside reviewJohn V Heymach, Sanjay Popat, Egbert F Smit, et al.European Journal of Endocrinology|November 12, 2014
GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETsThierry de Baere, Frederic Deschamps, Lambros Tselikas, et al.Acta Cytologica|December 5, 2012
Circulating tumor cells in lung cancerRachel Young, Emma Pailler, Fanny Billiot, et al.Bulletin Du Cancer|December 5, 2014
[Focus on targeting the Ras-MAPK pathway: the Mek inhibitors]Capucine Baldini, Boris Duchemann, Antoine Hollebecque, et al.Pageof 59